NYSE: CDRECadre Holdings Inc Stock
$30.45+0.55 (+1.84%)
Updated May 17, 2024
CDRE Price
$30.45
Fair Value Price
N/A
Market Cap
$1.24B
52 Week Low
$19.13
52 Week High
$39.81
P/E
29.85x
P/B
4.57x
P/S
2.7x
PEG
0.66x
Dividend Yield
0.26%
Revenue
$508.64M
Earnings
$38.57M
Gross Margin
41.6%
Operating Margin
11.09%
Profit Margin
7.6%
Debt to Equity
1.21
Operating Cash Flow
$63M
Beta
0.79
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CDRE Overview
Cadre Holdings, Inc. provides safety and survivability equipment to users (including first responders) in potentially hazardous or life-threatening situations in the U.S. and internationally. Offerings include body armor, explosive ordnance disposal equipment, duty gear, light sticks, chemiluminescent ammunition, and infra-red devices. It also sell third-party uniforms, boots, firearms, and ammunition. The company was founded in 1964 and is headquartered in Jacksonville, FL.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CDRE ($30.45) is trading above its intrinsic value of $21.71, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDRE is good value based on its earnings relative to its share price (29.85x), compared to the US market average (30.97x)
P/E vs Market Valuation
CDRE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CDRE due diligence checks available for Premium users.
Be the first to know about important CDRE news, forecast changes, insider trades & much more!
CDRE News
Valuation
CDRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
29.85x
Industry
21.79x
Market
30.97x
CDRE is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CDRE is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
CDRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.57x
Industry
5.62x
CDRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CDRE price to earnings growth (PEG)
For valuing profitable companies with growth potential
CDRE is good value based... subscribe to Premium to read more.
PEG Value Valuation
CDRE's financial health
Profit margin
Revenue
$137.9M
Net Income
$6.9M
Profit Margin
5%
CDRE's Earnings (EBIT) of $56.41M... subscribe to Premium to read more.
Interest Coverage Financials
CDRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$599.4M
Liabilities
$328.7M
Debt to equity
1.21
CDRE's short-term assets ($269.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDRE's short-term assets ($269.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.1M
Investing
-$142.6M
Financing
$139.8M
CDRE's operating cash flow ($62.62M)... subscribe to Premium to read more.
Debt Coverage Financials
CDRE vs Defense Stocks
Cadre Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.